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Purpose: To develop an hypoxia-regulated retinal pigment epithelium (RPE)-specific adeno-associated virus (AAV) gene
transfer platform that exploits hypoxia as a physiologic trigger for an early antiangiogenic treatment strategy directed at
arresting neovascularization in the eye.
Methods: Tissue-specific and hypoxia-regulated expression vectors were constructed with tandem combinations of
hypoxia responsive elements and aerobically silenced elements (HRSE) that together induce gene expression in hypoxia
and suppress it in normoxia. For RPE-specific expression, the HRSE and a (6x) HRE (hypoxia responsive element)
oligomer were ligated upstream of the Rpe65 promoter in a pGL3 firefly luciferase plasmid (pGL3-HRSE-6xHRE-
Rpe65). The cell specificity of this novel hybrid promoter was tested in human RPE (ARPE-19), human glioblastoma, rat
C6 glioma, mouse hippocampal neurons, and human embryonic kidney cell lines. Expression of all cell types in normoxia,
and following 40 h hypoxia, was analyzed by dual luciferase assay. After confirmation of its tissue-specificity and hypoxia-
inducibility, the hybrid promoter construct was integrated into a replication-deficient AAV delivery system and tested for
cell-selectivity and hypoxia-inducible green fluorescent protein (GFP) reporter expression.
Results: The HRSE-6xHRE-Rpe65 promoter was highly selective for RPE cells, strongly induced in hypoxia, and similar
in activation strength to the cytomegalovirus (CMV) promoter. The AAV.HRSE.6xHRE.Rpe65 vector induced robust
GFP expression in hypoxic ARPE-19 cells, but elicited no GFP expression in hypoxia in other cell types or in normoxic
ARPE-19 cells.
Conclusions: The hypoxia-regulated, aerobically-silenced RPE-targeting vector forms a platform for focal autoregulated
delivery of antiangiogenic agents in hypoxic regions of the RPE. Such autoinitiated therapy provides a means for early
intervention in choroidal neovascularization, when it is most sensitive to inhibition.
Gene transfer of an antiangiogenic gene to areas of focal
hypoxia in the retina or retinal pigment epithelium (RPE) may
provide  a  useful  approach  for  treatment  of  choroidal
neovascularization (CNV) in the “wet” form of age-related
macular  degeneration  (AMD)  [1,2].  Hypoxia-induced
changes in tissue physiology trigger ocular pathology [3-7].
This hypoxia-induced activation of gene expression can also
serve as a physiologic switch for activation of a therapeutic
response.
The sensing of tissue oxygen for such a switch occurs
through changes in hypoxia-inducible factor-1 (HIF-1). The
physiologic  response  to  tissue  hypoxia  is  initiated  by  the
binding  of  the  HIF-1  transcription  factor  to  the  hypoxia
response element (HRE) [8,9]. HIF-1 is a basic helix–loop–
helix protein formed by heterodimerization of HIF-1α and
HIF-1β,  which  are  both  constitutively  expressed  [10,11].
Under  normoxic  conditions,  oxygen-dependent
hydroxylation of prolyl residues of HIF-1α targets it for rapid
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ubiquination and degradation by the proteosome; in contrast,
HIF-1β is unregulated [12,13].
In hypoxic conditions, heterodimerization of HIF-1α and
HIF-1β forms HIF-1, which translocates to the nucleus to bind
HREs  and  upregulate  gene  expression  [14].  The  core
consensus sequence for the HRE is (A/G)CGT(G/C)C, which
occurs in the 5′ or 3′ flanking sequences of greater than 60
hypoxia-regulated  genes  identified  to  date  [15].  Thus
implementation  of  HRE  consensus  sequences  exploits  an
endogenous, exquisitely sensitive regulatory pathway as a
physiologic  switch  for  hypoxia-regulated  delivery  of  a
therapeutic gene.
A major potential concern regarding gene therapy is that
surrounding tissue may be adversely affected after prolonged
exposure to the transgene. Most existing gene therapy vectors
express the transferred gene product at a constant level in all
tissue types exposed to the vector, resulting in high level
transgene  expression  outside  of  the  intended  therapeutic
region. Adenoviral-mediated transgene expression typically
persists only days to weeks before clearance by the immune
system and often stimulates an inflammatory response [16].
Because of rapid clearance chronic expression has not been a
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471major concern. More recently, novel adeno-associated virus
(AAV) vectors have been designed to stay functional for years
and possibly the lifetime of the patient; therefore extended
exposure to elevated transgene levels in adjacent tissue might
produce a higher risk for dysplasia.
Hypoxia is found in several pathological conditions and
has been recognized as a potential pathological regulator for
gene  therapy.  Hypoxia-regulated  gene  therapy  has  been
successfully  demonstrated  in  several  disease  models,
including cardiac ischemia [17,18], cancer [19-22], and ocular
angiogenesis [23]. Tissue-specific vectors have already been
constructed for selective gene expression in neurons [24],
endothelial cells [25], cardiac tissue [18,26], photoreceptors
[27,28], and RPE [29]. The RPE is an excellent target for gene
therapy in the posterior eye due to its location between the
retina  and  the  choriocapillaris,  and  adjacent  to  Bruch’s
membrane where inflammatory processes contribute to AMD.
It may therefore be appropriate to target the RPE in either
geographic atrophy or CNV.
Therapeutic targeting of the RPE can be achieved by
using the Rpe65 promoter, which is constitutively activated
in the RPE but not in other retinal cell types [30]. Rod and
cone  photoreceptor  function  in  a  canine  model  of  Leber
congenital amaurosis was successfully restored with a cell-
specific therapy targeted to the RPE using the Rpe65 promoter
[31].  Coupling  this  promoter  with  a  hypoxia-regulated
cassette  would  create  a  gene  therapy  that  would  support
delivery  in  focal  hypoxia.  An  added  benefit  is  that  gene
therapy could theoretically be titrated to the degree of hypoxia
since more severe hypoxia would result in greater expression
of the transgene. The optimal inducible expression system for
delivery of an antiangiogenic agent should have low basal
promoter  activity  in  the  nontherapeutic  or  normoxic
environment. After gene transfer, the therapy should remain
quiescent until activated by a pathological trigger such as
hypoxia. Data presented here documents hypoxia-regulated
expression of green fluorescent protein (GFP) within RPE
cells, but not other cell lines, transfected with AAV-vectors.
Thus, although other cell types may be transfected with the
vector,  transgene  expression  will  be  restricted  to  foci  of
hypoxic RPE cells.
METHODS
Cell cultures and reagents: The ARPE-19 (human retinal
pigment epithelium), HepG2 (human hepatoma), and A-172
(human  glioblastoma)  cell  lines  were  purchased  from  the
American  Type  Culture  Collection  (Manassas,  VA).
HEK-293 (human embryonic kidney) cells were purchased
from Stratagene (La Jolla, CA). HT22 (mouse hippocampal
neurons) cells were a kind gift from Dr. David R. Schubert
(The Salk Institute, San Diego, CA). C6 glioma cells were a
kind gift from Dr. Ajay Verma (Uniformed Health Services
University, Bethesda, MD). Cell cultures were maintained in
Dulbecco’s  modified  eagle  medium  (DMEM)  (Cellgro-
Mediatech,  Herndon,  VA)  supplemented  with  10%  fetal
bovine  serum  (HyClone,  Logan,  UT)  and  1%  penicillin/
streptomycin (Cellgro-Mediatech).
Design  and  construction  of  retinal  pigmented  epithelium-
specific and hypoxia-inducible promoters for reporter gene
expression plasmids: The HRE sequence is from the human
phosphoglycerate kinase (PGK) gene in the sense orientation
5′-TGT CAC GTC CTG CAC GAC GTA-3′. The neuron-
restrictive silencer element is the sequence from the human
synapsin I gene in the sense orientation, 5′-TTC AGC ACC
GCG GAC AGT GCC-3′ [32]. The Rpe65 promoter (−325 to
+52) was derived from the 5′ upstream sequence of the Rpe65
gene (a generous gift from Dr. Michael Redmond) [30]. Three
copies of the neuron-restrictive silencer element and three
copies of the HRE were placed in alternating tandem order to
form the hypoxia-regulated silenced element (HRSE; kindly
provided by Dr. Keith Webster), which is a promoter designed
to be conditionally silenced in normoxia and robustly induced
during in hypoxia (Figure 1A). Regulation of gene expression
by combined tandem arrays of HRE and silencer elements has
been described previously [33,34]. Additionally, six tandem
HRE copies were synthesized (e-oligos, Hawthorne, NY) into
one  oligomer  (6xHRE),  which  functions  to  enhance  the
hypoxic  activity  of  the  promoter  (K.  Webster,  personal
communication). This oligomer was synthesized as two 144
bp synthetic complementary oligos annealed into a double-
Figure 1. Diagram of the aerobically silenced, hypoxia-regulated
promoter enhancer. A: Three copies of the neuron-restrictive silencer
element (NRSE) and three copies of the hypoxia-regulated enhancer
(HRE) were placed in alternating tandem order to form the hypoxia-
regulated silenced element (HRSE), which is conditionally silenced
during  aerobic  periods  and  robustly  induced  in  hypoxia.  This
3xHRSE domain is composed of the NRSE (S) and the HRH (H)
tandemly repeated three times. This domain is ligated to a 6xHRE
domain, which is six additional tandem repeats of the HRE. B: The
table  graphic  represents  the  four  pGL3-based  firefly  luciferase
reporter plasmids constructed to test the relative activities of the
hybrid and control promoters.
Molecular Vision 2008; 14:471-480 <http://www.molvis.org/molvis/v14/a56> © 2008 Molecular Vision
472stranded  oligonucleotide  with  Sac  I  restriction  sites
incorporated at each termini. The HRSE and 6xHRE regions
were ligated upstream of the RPE65 promoter for expression
analysis  in  a  pGL3  luciferase  reporter  vector  (Promega,
Madison, WI), (Figure 1B). The reporter plasmids constructed
were  pGL3-HRSE,  pGL3-HRSE-Rpe65  and  pGL3-
HRSE-6xHRE-Rpe65. To gauge the relative strength of the
hypoxic induction, expression plasmids encoding individual
Rpe65  or  cytomegalovirus  (CMV)  promoters  were  also
constructed for direct comparison of the hybrid promoter to
the parent tissue specific promoter (Rpe65) and to CMV.
Plasmid transfection, hypoxia treatment, and dual luciferase
assay: The pGL3 based reporter constructs were transiently
transfected  by  polycationic  liposomes  (GeneFector™,
VennNova Inc., Pompano Beach, FL) with pGL3-TK-Renilla
(transfection  control  plasmid)  into  ARPE-19,  HEK-293,
HT22 and C6 glioma cells cultured on 24 well plates (Greiner
Bio-One, Monroe, NC) at a total concentration of 1µg DNA
per well. The average transfection efficiency was around 70%.
Cells were maintained in Dulbecco’s modified eagle medium
(DMEM) supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin and fed one hour before transfer to
either  the  Bactron  Anaerobic  Environmental  Chamber
(Sheldon Manufacturing Inc., Cornelius, OR) maintained at
pO2=1.0%, or a cell culture incubator (pO2=20.8%) for the
experimental time course of 40 h at 37 °C. Chamber hypoxia
was maintained at 1% O2, 89% N, 5% CO2, 5% H. Chamber
oxygen  was  continuously  monitored  using  a  MI-BASO2
oxygen  electrode  (Microelectrodes  Inc.,  Bedford,  NH).
Culture  plates  were  introduced  to  and  removed  from  the
chamber through a small side bypass chamber. Cultures were
fed with hypoxic media inside the chamber using an integrated
glove system. Cells were isolated from either normoxia or
hypoxia then lysed and assayed using the dual luciferase assay
per the manufacturer's protocol (Dual Luciferase Assay Kit;
Promega,  Madison,  WI).  Results  are  presented  as  fold
induction with respect to a normalized normoxic luciferase
activity measured in relative light units (rlu). All experiments
were repeated at least twice and measured in triplicate each
time.
Construction  and  production  of  recombinant  adeno-
associated virus vectors: The Helper-Free AAV System©
(Stratagene) permits the production of replication deficient
recombinant human AAV, serotype-2 without the use of a
helper virus. The pAAV-IRES-hrGFP shuttle plasmid was
subcloned to remove the CMV promoter using a Mlul/Sall
restriction enzyme digest to allow the introduction of the
HRSE-6xHRE-Rpe65  cassette.  The  HRSE-6xHRE-Rpe65
promoter cassette was cloned into the pAAV-IRES-hrGFP
expression  plasmid  using  the  multiple  cloning  site.
Propagation of the recombinant AAVs was conducted per the
manufacturer’s protocol. Briefly, AAV-293 cells were triple
transfected  by  the  calcium  phosphate  method  using  the
pAAV-HRSE-6xHRE-Rpe65 in conjunction with pAAV-RC
and pHelper plasmids for 66 to 72 h before freeze thaw lysis
and purification of AAV. Both experimental AAV.HRSE.
6xHRE.Rpe65.GFP  and  control  AAV.CMV.GFP  viruses
were constructed.
Infection  of  cell  culture  with  adeno-associated  virus:
ARPE-19, HT22, HEK-293, and C6 glioma cell cultures were
transfected with AAV.HRSE.6xHRE.Rpe65.GFP at a moiety
of  infection  of  10  and  cultured  for  seven  days  before
experimental exposure to normoxia or hypoxia for 40 h before
fluorescence microscopy to detect the expression of GFP. On
average, 99% of the cells were transfected with AAV.
Statistical analysis: Results are expressed as mean ± standard
deviation.  Differences  between  groups  were  evaluated  by
two-tailed Student’s t-test. The significance of the hypoxic
induction and silencing measured by DLA was determined by
ANOVA using InStat 3.0b statistical software for Apple OS
X.
RESULTS
Conditionally  silenced  gene  expression  in  normoxia:  The
aerobic  activity  profile  of  the  basal  Rpe65  promoter  was
compared  to  the  HRSE-6xHRE-Rpe65  promoter  using  a
Figure  2.  Normoxic  dual  luciferase  expression  using  the  Rpe65
promoter  and  the  HRSE-6xHRE-Rpe65  promoter  in  transiently
transfected  ARPE-19  cells.  ARPE-19  cells  were  transiently
transfected by cationic lipid and exposed to forty hours of normoxia.
The silencing of basal activity from the RPE65 promoter, under
normal aerobic conditions, was due to the integration of the three
neuron-restrictive silencer elements within the hypoxia-regulated
aerobically silenced element (HRSE). The activity of all promoters
tested was normalized to the Rpe65 promoter. The addition of the
silencer elements in the HRSE reduced the normoxic activity of the
Rpe65  promoter  by  64%  from  1.0  to  0.4±0.1  (n=6,  p<0.001).
Addition  of  six  hypoxia-regulated  elements  (HREs)  in
HRSE-6xHRE-Rpe65 reduced the normoxic activity of the Rpe65
promoter by 79% from 1.0 to 0.2±0.1 (n=8, p<0.001). Asterisks (*)
indicates statistical significance.
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473DLA. Transiently transfected ARPE-19 cells were exposed to
40 h of normoxia. The activity of the Rpe65 promoter was
normalized to one. Interestingly, addition of the three silencer
elements in the (3x) HRSE to the Rpe65 promoter reduced the
normoxic activity of the Rpe65 promoter by 60% from 1.0 to
0.4±0.1 (n=6, p<0.001) (Figure 2). With the addition of six
more HREs, the normoxic activity of the Rpe65 promoter was
reduced by 80% from 1.0 to 0.2±0.1 (n=8, p<0.001).
Hypoxia-inducible gene expression of HRSE-6xHRE-Rpe65:
Progressive increases in the number of HREs led to a 51-fold
increase in gene depression in hypoxia. Enhanced expression
of each construct occurred in ARPE-19 cells transfected by
cationic lipid and cultured for 40 h in hypoxia. Relative to the
aerobic  activity  of  the  Rpe65  promoter,  the  basal  Rpe65
promoter activity was increased to a small degree by 1.6±0.3
fold (n=7, p>0.05) in hypoxia (Figure 3). Ligation of this
Rpe65 promoter to an upstream HRSE resulted in a 9.4±5.7
Figure  3.  Hypoxic  dual  luciferase  expression  in  ARPE-19  cells
transfected with the Rpe65 promoter, the HRSE-Rpe65 promoter
containing  three  hypoxia-regulated  elements,  and  the
HRSE-6xHRE-Rpe65 promoter. The addition of the three hypoxia-
regulated elements (HREs) in HRSE-Rpe65 accounts for a modest
increase in basal Rpe65 inducibility (black). Transiently transfected
cell lines were exposed to forty hours of hypoxia (black) or normoxia
(white). All promoter activity was normalized to the aerobic activity
of the Rpe65 promoter. A small hypoxic induction of 1.6±0.3 (n=7,
p>0.05) fold was identified in the native Rpe65 promoter. Ligation
of an upstream HRSE to the Rpe65 promoter resulted in a 9.4±5.8
(n=9, p<0.001) fold hypoxic induction due to three HREs present in
the HRSE. Addition of the 6xHRE oligomer brings the total number
of HREs to nine and accounts for the 51.3±10.8 (n=10, p<0.001) fold
increase in hypoxia inducibility over aerobic baseline. Asterisks (*)
indicate statistical significance.
fold (n=9, p<0.001) induction. Hypoxic induction was further
Figure  4.  Demonstration  of  cell-specificity.  A:  Comparison  of
hypoxia  induced  dual  luciferase  activity  of  the  HRSE-6xHRE-
RPE65 promoter in retinal pigmented epithelium (ARPE-19) cells
with other cell types. The activation of the HRSE-6xHRE-Rpe65
promoter in ARPE-19 cells exposed to 1% oxygen for 40 hours was
51.3±10.8  (n=10,  p<0.001)  fold  over  aerobic  activity.  The  non-
epithelial cell lines displayed a relatively minimal activation of the
HRSE-6xHRE-Rpe65 promoter throughout the same hypoxic time
course  confirming  a  hypoxia-inducible  and  cell-specific  gene
expression  regulated  by  the  HRSE-6xHRE-Rpe65  promoter
construct. Hypoxia-mediated promoter activation for the tested cell
lines  were:  HT22  mouse  hippocampal  neuron  (4.3±1.6,  n=9,
p<0.001),  HEK-293  human  embryonic  kidney  (3.3±2.5,  n=6,
p<0.001),  C6  glioma  (2.8±0.3,  n=5,  p<0.001)  and  A-172
glioblastoma (1.2±1.4, n=3, p<0.001). B: The relative strength of the
HRSE-6xHRE-Rpe65  promoter  in  hypoxia  is  comparable  to
cytomegalovirus  (CMV).  The  histogram  illustrates  that  the
HRSE-6xHRE-Rpe65 promoter activity was similar to the CMV
promoter under hypoxic conditions. Under aerobic conditions the
CMV promoter activity remains strong while the HRSE-6xHRE-
Rpe65  promoter  is  conditionally  silenced.  Asterisks  (*)  indicate
statistical significance.
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474increased with the addition of six tandem HREs inserted at a
position between the HRSE and the Rpe65 promoter. With a
total  number  of  nine  HREs,  the  HRSE-6xHRE-Rpe65
promoter  in  hypoxia  increased  51.2±10.8  fold  (n=10,
p<0.001; see Figure 3). Preliminary data indicate that 40 h of
hypoxia is sufficient to induce a maximal response of this
hypoxia-regulated promoter (data not shown).
Inducible gene expression of HRSE-6xHRE-Rpe65 in non-
target cell lines: To further characterize cell-specificity of the
HRSE-6xHRE-Rpe65  promoter  construct,  we  transiently
transfected several additional nontarget cell lines, including
HT22, HEK-293, C6 Glioma, HepG2, and A-172, exposing
them to hypoxia for 40 h before analysis by DLA. In contrast
to the 51.2 fold increase in luciferase activity observed in
hypoxic ARPE-19 cells, the promoter supported only minimal
(more  than  tenfold  smaller)  response  to  hypoxia  in  the
nontarget cell lines (Figure 4A). Hypoxia-mediated promoter
activation in these tested cell lines was HT22 (4.3±1.6; n=9,
p<0.001),  HEK-293  (3.3±2.5;  n=6,  p<0.001),  C6  glioma
(2.8±0.3; n=5, p<0.001), and A-172 (1.2±1.4; n=3, p<0.001).
To predict the level of transgene expression in hypoxic
ARPE-19 cells, we used a DLA to compare the promoter
strengths of the HRSE-6xHRE-Rpe65 promoter construct and
a  CMV  promoter  construct.  Figure  4B  indicates  that  the
HRSE-6xHRE-Rpe65 promoter activity was almost as strong
as  the  CMV  promoter  under  hypoxic  conditions.  Under
aerobic  conditions,  the  CMV  promoter  activity  remained
strong  whereas  the  HRSE-6xHRE-Rpe65  promoter  was
conditionally silenced.
Cell  specificity  of  inducible  green  fluorescent  protein
expression in AAV-HRSE-6xHRE-Rpe65 infected cell lines:
The HRSE-6xHRE-Rpe65 promoter was used to produce a
replication-deficient  AAV  serotype  2  for  cell  culture
transfection.  Figure  5  shows  representative  phase  and
fluorescence images of the different cell lines after 40 h of
hypoxia. Hypoxic ARPE-19 cells clearly demonstrated strong
induction  of  GFP.  The  other  cell  lines  did  not  produce
detectable  GFP  under  these  conditions.  Constitutive
expression  of  GFP  in  normoxic  cells  transfected  with
AAV.CMV.GFP  is  also  shown  in  Figure  5.  When  the
transfected ARPE-19 cells were returned to normoxia, the
GFP level declined rapidly and was barely detectable at 72 h
(data not shown). The fact that GFP has a half-life of 26 h
suggests that the promoter is rapidly suppressed in oxygen.
DISCUSSION
This  report  demonstrates  a  new  hypoxia-regulated  gene
expression  platform  specific  for  the  RPE.  Induction  of
hypoxia-responsive promoters in disease models in vivo has
previously  been  reported  [23,26,35].  To  achieve  hypoxia-
regulated gene expression, previous reports have employed
different HREs, such as from PGK [36]. Specifically, Boast
et al. achieved more than a 50-fold hypoxic induction with
PGK-HREs. Bainbridge et al. later constructed a hypoxia-
responsive vector by placing three PGK-HREs upstream of a
GFP reporter in a recombinant AAV [23]. The vector drove
retinal GFP expression in a mouse model of laser-induced
retinal hypoxia. One drawback of this vector was a readily
detectable  expression  of  GFP  in  control  mice,  indicating
significant basal activity of the HRE enhancer/promoter under
aerobic conditions. Our approach differs in that the basal
activity  of  our  HREs  is  tempered  by  engineered  silencer
elements that reduce the basal transcriptional activity of the
HREs and the downstream tissue-specific promoter.
Potentially deleterious effects of gene therapy can be
minimized by limiting expression of a transgene to the area of
diseased tissue, so that therapy occurs only at the right time,
and in the right place. Expression of a transgene at the “wrong”
time or place (i.e., in healthy tissue) might result in detrimental
consequences for tissue survival. Our cell-specific, hypoxia-
regulated platform would deliver antiangiogenic agents only
in the immediate locale of hypoxic RPE cells.
Vectors containing only multiple copies of HREs are not
optimal because they exhibit high basal levels of expression
in normoxia. To achieve maximal inducibility in response to
hypoxia it is necessary to obtain very low levels of basal
expression  using  a  tissue-specific  silencer  that  binds  and
blocks the promoter during aerobic exposure [37,38]. It has
previously  been  demonstrated  in  vivo  that  a  promoter
containing a neuronal silencer element is inactive at normal
oxygen in all tissues except brain, as its function is to silence
neuronal  gene  expression  in  nonneuronal  tissue  [38].
Specifically,  a  promoter  containing  both  copies  of  the
neuronal  silencer  plus  the  HRE  was  induced  several
hundredfold by hypoxia in cardiac tissue with the use of a
tissue-specific basal promoter [37,38]. These HRE enhancer
elements  were  also  constructed  with  multiple  alternating
copies  of  HREs  and  silencer  elements.  Furthermore  cell
culture and in vivo studies demonstrated that the hypoxia-
regulated promoters have the potential to be robustly induced
when employed in combination with different tissue-specific
basal promoters [39,40].
With the incorporation of three HREs in the HRSE to the
promoter, the hypoxia response increased from 1.6 fold with
the basal Rpe65 promoter to 9.4 fold (Figure 3). In this novel
paradigm, transcription is activated by hypoxia, when HIF-1
displaces the silencer protein and permits transcription. The
use of these multiple neuronal-restrictive silencer elements
(Figure 1) generated an impressive 80% reduction of basal
Rpe65 promoter activity (Figure 2). This reflects the type of
response expected from the silenced promoter in a normal
oxygenated environment where expression of a transgene is
not expected or required. The ability to titrate the amount of
growth factor delivered to focal regions in the posterior eye
would avoid “overtreating” a larger area where therapy is not
required. This strict promoter regulation may prove useful in
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475future gene therapy applications in the eye as well as in other
organs.
Under normal aerobic conditions, the embedded silencer
elements would function to diminish the “leakiness” typically
observed in promoter constructs. The combination of aerobic
silencing and strong hypoxic induction demonstrates that the
promoter  construct  HRSE-6xHRE-Rpe65  is  ideal  for
regulating hypoxic expression in ARPE-19 cells.
Although numerous reports document that ocular gene
therapy mediated through viral vectors has the potential to
treat  neovascularization  [41-46],  to  delay  photoreceptor
degeneration [47-50], and to suppress immune response [51],
little attention has been paid to cell targets, the ocular location
for  optimal  delivery  of  the  therapeutic  factor,  or  to  the
physiologic  conditions  in  the  retina  being  treated.  Tight
transcriptional regulation has recently been combined with
cell-specific promoters, such as Rpe65 for RPE cells [30], to
regulate both the level and location of transcription [52]. The
cell-specific and hypoxia-regulated vector reported here is
likely  to  lay  the  foundation  for  further  rational  design
strategies for ocular gene therapy vectors.
Initially, it was predicted that the minimal activation of
HRSE-6xHRE-Rpe65 quantitated in the non-RPE luciferase
assays  (Figure  4)  would  directly  correlate  with  GFP
expression in cells transfected with HRE-regulated AAVs.
Transfected ARPE-19 cells exposed to hypoxic conditions did
indeed produce a robust cytosolic GFP expression analogous
to that seen in the luciferase assays, but there was no detectable
GFP expression in the hypoxic non-target cell lines (Figure
5). These results are not surprising since luciferase assays are
far  more  sensitive  than  detection  of  GFP  by  fluorescent
microscopy. These sensitive changes in GFP production also
may be detectable at the RNA level using RT–PCR.
The role of hypoxia in the pathophysiology of vascular
endothelial growth factor (VEGF) upregulation in wet AMD
remains undefined [3,53,54]. There is evidence suggesting a
role  for  both  focal  hypoxia  and  inflammatory  cytokines.
Ramrattan et al. described that older eyes, and especially those
Figure  5.  Hypoxia-inducible  green
fluorescent  expression  is  specific  to
ARPE-19  cells  transfected  with
AAV.HRSE.6xHRE.Rpe65.GFP.
Hypoxia-inducible  green  fluorescent
protein (GFP) expression is specific to
RPE (ARPE-19) cells transfected with
the  AAV.HRSE.6xHRE.Rpe65.GFP
vector.  Cells  were  transfected  with
AAV.HRSE.6xHRE.Rpe65.GFP  and
cultured  for  seven  days  before  forty
hours of hypoxia (pO2=1%). Hypoxia-
inducible GFP expression is specific to
only  ARPE-19  cells  and  was  not
detected  in  transfected  HT22  mouse
hippocampal neurons, HEK-293 human
embryonic  kidney  or  C6  glioma  cell
lines cultured under similar conditions.
Duplicate phase contrast images detail
the morphology of the transfected cell
lines in column one. In column three,
representative  images  of  control
cultures infected with AAV.CMV.GFP
express  GFP  constitutively  during
normoxic conditions.
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476with  AMD,  exhibited  significant  loss  of  choriocapillaris,
which would–at least theoretically–result in focal hypoxia
[55]. This would be likely lead to regions of focal hypoxia in
the overlying RPE. There is substantial evidence supporting
the possibility of production of inflammatory cytokines as
well as oxidative species in eyes with AMD [56,57]. While
we use 1.0% oxygen as the hypoxic stimulus for the activation
of our HREs, we found this promoter is sensitive to less severe
hypoxia.  Experiments  are  ongoing  to  characterize  the
response of this vector in conditions of less severe hypoxia
(data not shown).
While hypoxia results in enhanced VEGF production,
stimuli other than hypoxia may act via HIF-1α to induce
VEGF  and  elicit  neovascularization.  Stress-induced
molecules such as Interleukin 1-beta (IL-1β), tumor necrosis
factor alpha (TNF-α), nitric oxide, lipid hydroperoxide, and
transforming  growth  factor  beta  (TGF-β)  all  have  been
documented to signal through HIF-1 [58-62]. Oxidative stress
induced by cobalt chloride or desferrioxamine has also been
demonstrated to induce significant HIF-1α signaling [63,64].
Oxidative conditions also stimulate neovascular events [65,
66]. Thus, our HIF-1-regulated vector would be activated by
several  proangiogenic  conditions,  including  hypoxia,
oxidative stress, as well as inflammation, all of which have
been implicated in AMD. Our ongoing studies are examining
the  activation  of  the  HRSE-6xHRE-Rpe65  promoter  by
oxidative stress.
The possible use of the HRSE-6xHRE-Rpe65 promoter
as a platform for therapy against neovascularization is being
tested  in  vivo  in  both  AMD  and  proliferative  diabetic
retinopathy models. Both diseases are candidates for gene
therapy  because  neovascularization  is  preceded  by  well
defined markers of high risk. Although the construct we report
is as strong as CMV, a major advantage of our strategy is that
it is possible to vary the dosage of the transgene product by
varying the number of HREs. Successful inhibition of CNV
in murine models will further demonstrate the therapeutic
potential  of  the  HRE-driven  endostatin  [67]  AAV.
Experiments  to  test  this  promoter  driving  endostatin  in  a
mouse model of CNV are in progress.
In summary, our data demonstrate hypoxia-induced AAV
vectors for delivery specifically to the RPE. These vectors will
be used to evaluate therapeutic efficacy of therapies targeted
to these retinal locations. Moreover, because these vectors
transform proangiogenic signal transduction pathways into
switches for local delivery of antiangiogenic agents, they lay
a foundation for new therapies that intervene in angiogenic
diseases at their earliest stages, before tissue disruption or scar
formation.
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